[1] |
ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie.
Adverse reaction monitoring of toothpaste in China under the new regulatory system
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222.
|
[2] |
GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe.
Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5.
|
[3] |
ZHANG Li, WANG Yujia, ZHANG Lingling, CHEN Jiaxin, LIN Minhua, LIN Xiaohui, NIE Xuekun.
Surveillance data on adverse reactions associated with real-world immune checkpoint inhibitors
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1035-1038.
|
[4] |
YU Hongli, YU Dongmei, XIAO Aili, ZHU Lan, SONG Haibo.
Risks of safety Qingkailing oral preparation
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1046-1048.
|
[5] |
ZOU Dongmei, FANG Fang, GUO Yixian, NI Jing, ZHAO Hong, HU Ronghua, SUN Wanling.
Analysis of the association of adverse reactions with relative dose of melphalan and body weight in POEMS syndrome patients undergoing melphalan-based ASCT
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 911-914.
|
[6] |
YANG Le, XIA Dongsheng, WANG Tao.
Risks to safety of vitamin B6 injection
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 791-794.
|
[7] |
ZHAO Wenhua, SHU He, NI Chenming, GUO Jinmin.
Data mining and analysis of adverse drug reaction signals of fampridine sustained-release tablets based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 684-690.
|
[8] |
JIAO Fuzhi, CHEN Yarui, JI Wei, HAO Jianpeng, GUAN Quanlin.
Short-term efficacy and safety evaluation of PD-1 inhibitor combined with chemotherapy as a first-line neoadjuvant therapy for locally advanced gastric adenocarcinoma
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 301-305.
|
[9] |
LIU Zhike, ZHAN Siyan.
Progress in applications of self-controlled designs in association study of vaccine safety
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 74-78.
|
[10] |
CUI Can, WEI Hongtao, CHENG Sheng, SHEN Su.
Adverse reactions induced by teriparatide
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 333-335.
|
[11] |
LIU Min, PEI Xiaojing, WANG Haixue.
Problems with and suggestions about expedited reporting of suspected unexpected serious adverse reactions during clinical trials of drugs in China
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 176-179.
|
[12] |
WU Chen, LIU Cuili, WANG Tao.
Cardiovascular safety of haloperidol preparations
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1100-1102.
|
[13] |
ZHANG Dan, LYU Jintao, SONG Haibo, ZHANG Bing, JIN Yongnan, SA Rina, ZHANG Xiaomeng, LIN Zhijian.
Drug Risk Communication among Drug Regulatory Agencies in the European Union, the United States and Asia
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(9): 845-849.
|
[14] |
LI Lan, KONG Fanyao, ZHU Ying, SHEN Lu.
Developments and Suggestions on Cosmetics Adverse Reaction Monitoring in China
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(9): 850-854.
|
[15] |
SUN Xuelin, ZHANG Yatong, HU Xin.
Investigation of Public Perceptions of Drug Use Risks
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(9): 860-863.
|